Cohance Lifesciences to invest ₹23 cr in a new facility in Hyderabad

Cohance Lifesciences will be investing ₹23 crore (₹230 million) in its new Current Good Manufacturing Practice (cGMP) oligonucleotide building block manufacturing facility in Hyderabad. 

 “Oligonucleotides are a fast-emerging therapeutic class, and innovators are seeking integrated, cost-efficient partners with scalable GMP capacity. This facility is a high-impact strategic investment that complements our pilot and scale-up assets, positioning Cohance to deliver with speed, quality and flexibility while expanding our role in next-generation therapeutics,’‘ Vivek Sharma, Executive Chairman, Cohance Lifesciences on Tuesday.

The new facility will enable the company to take high-value chemistries from laboratory scale to full commercial manufacturing, meeting the needs of innovators advancing oligonucleotide-based therapeutics.

Integrated with a pilot plant for early-stage synthesis and for non-GMP scale-up, the facility will add fit-for-purpose GMP capacity of up to 700 kg annually, with room for future expansion.

Customer engagements are already underway, with audits planned in the coming quarters. Kilo lab validations and modified nucleotides are in progress, the company said.

This investment follows the company’s recently announced $10 million expansion of cGMP bioconjugation capabilities at NJ Bio in the United States. Together, these investments form part of Cohance’s planned capacity expansion program across high-growth modalities, enhancing its ability to serve global innovators from early development to commercial supply.

Cohance Lifesciences, formerly Suven Pharmaceuticals, is an innovator-focused global Contract Research, Development and Manufacturing Organisation (CRDMO) formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals.

Published on August 12, 2025